Poxel Announces Availability of Its 2021 Universal Registration Document
04 Maggio 2022 - 8:45PM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced that the Universal Registration Document (Document
d’Enregistrement Universel) for the year ended December 31, 2021
has been filed with the French market authority (Autorité des
Marchés Financiers, or AMF).
This document is available in English on the AMF’s website and
on Poxel’s website www.poxelpharma.com in the Investors /
Shareholder Information / Regulatory Documentation section (in
English and in French).
The 2021 Universal Registration Document includes:
- the 2021 Annual Financial Report, including the Management
Report; and
- the Report on Corporate Governance
This year, the Company’s URD includes a new version of the
Corporate Social Responsibility (CSR) Report. This document
reflects the review and evaluation of Poxel existing CSR actions
performed in 2021, and describes its CSR strategy. The report will
be available on the Company’s website, in the Investors /
Corporate-governance section.
Printed copies of the universal registration document are also
available to the public free of charge and upon request at the
Company’s headquarters located Immeuble Le Sunway, 259-261 Avenue
Jean Jaurès, 69007 Lyon, France.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. Poxel has clinical
and earlier-stage programs from its adenosine
monophosphate-activated protein kinase (AMPK) activator and
deuterated TZD platforms targeting chronic and rare metabolic
diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY-1). PXL770, a first-in-class direct AMPK
activator, has successfully completed a Phase 2a proof-of-concept
trial for the treatment of NASH, which met its objectives. For the
rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product
that targets mitochondrial dysfunction, has been approved and
launched for the treatment of type 2 diabetes in Japan. Poxel
expects to receive royalties and sales-based payments from Sumitomo
Pharma. Poxel has a strategic partnership with Sumitomo Pharma for
Imeglimin in Japan, China, South Korea, Taiwan and nine other
Southeast Asian countries. The Company intends to generate further
growth through strategic partnerships and pipeline development.
Listed on Euronext Paris, Poxel is headquartered in Lyon, France,
and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504006115/en/
Investor relations / Media Aurélie Bozza Investor
Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36 Elizabeth Woo
Senior Vice President, Investor Relations & Communication
elizabeth.woo@poxelpharma.com NewCap Emmanuel Huynh or Arthur
Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024